People with elevated eye pressure, a condition called ocular hypertension, are quietly told they’re at risk for glaucoma and then handed a watch-and-wait approach. New data published in July 2026 suggests a common, inexpensive vitamin supplement may change that picture significantly, and the gap between those who took it and those who didn’t is hard to ignore.
A 2026 study published in JAMA Ophthalmology found that supplementation with vitamin B3 is associated with a 66% lower risk of developing glaucoma in people with high eye pressure. The vitamin in question is nicotinamide, also known as niacinamide, a form of B3 that most people associate with skincare products rather than eye health. Its potential to help vitamin prevent vision loss on this scale is reshaping how researchers think about glaucoma’s earliest stages.
Glaucoma is a group of eye diseases that gradually damage the optic nerve, often without any warning signs, and is linked to increased pressure inside the eye. If left untreated, it can lead to permanent vision loss. That slow, silent progression is precisely what makes it so dangerous. By the time someone notices a change in their peripheral vision, meaningful damage has already been done. According to the Glaucoma Research Foundation, approximately 80 million people worldwide had glaucoma as of 2020, with 60 million of those affected by the open-angle form.
The question researchers asked was simple: among people who already have elevated eye pressure and haven’t yet developed glaucoma, does nicotinamide slow the disease’s arrival? The answer from a 20-year dataset was striking.
What the 2026 Study Found
Researchers analyzed anonymous electronic health records collected from 67 healthcare organizations across the United States, covering data from March 2006 to March 2026. They identified 2,920 patients who had ocular hypertension but had not yet developed glaucoma. Half were taking nicotinamide, and the others were not. To make the comparison reliable, researchers used propensity score matching, pairing each nicotinamide user with a non-user of similar age, sex, and medical history.
Over a mean follow-up of 3.7 years, 51 patients taking nicotinamide developed primary open-angle glaucoma (POAG) compared with 132 in the control group, translating to 3.5% versus 9.0% and a 66% relative reduction in risk. The protective effect didn’t stop at diagnosis rates. Prescription eye drops to lower intraocular pressure were initiated in 13.6% of the nicotinamide group versus 21.2% in the control group. Laser trabeculoplasty, a procedure used to improve fluid drainage from the eye, was performed in just 0.8% of the nicotinamide group versus 1.9% of controls.
The study was led by Dr. Jawad Muayad of Texas A&M University in Houston and published online on July 9 in JAMA Ophthalmology.
In an editorial accompanying the study, Dr. Simon K. Law of the Stein Eye Institute at the University of California, Los Angeles wrote that “while the clinical significance and long-term benefit of nicotinamide in glaucoma remain to be established, this study adds to the growing body of laboratory, early human, and real-world evidence suggesting potential promise,” and that the field now awaits results from ongoing randomized clinical trials.
Why Glaucoma Is So Hard to Stop
Primary open-angle glaucoma is one of the leading ocular diseases leading to irreversible blindness and is often asymptomatic until advanced cases. Even with existing treatments, which focus almost entirely on reducing intraocular pressure with eye drops, lasers, or surgery, many patients continue losing vision. That’s because lowering eye pressure addresses one risk factor but does nothing to protect the nerve cells themselves from dying.
Glaucoma frequently advances even when intraocular pressure management is clinically adequate. Accumulating research points to the metabolic vulnerability of retinal ganglion cells, specifically around the progressive depletion of NAD+, a coenzyme fundamental to mitochondrial energy production and cellular survival.
Retinal ganglion cells are the neurons that carry visual signals from the eye to the brain through the optic nerve. They are highly energy-dependent, and research published in 2021 confirms they are among the most vulnerable cell types when mitochondrial function is impaired. When NAD+ levels fall, these cells lose the energy they need to survive, and the damage becomes irreversible.
Research has also shown that glaucoma patients have systemically lower levels of nicotinamide in their blood serum, supporting the hypothesis that pathogenically low NAD+ may increase susceptibility to glaucoma.
How Nicotinamide Fits Into the Picture
Nicotinamide, also known as niacinamide, is a precursor of NAD+ and has shown neuroprotective potential in preclinical models. By boosting NAD+ levels, it theoretically gives those vulnerable retinal cells the metabolic fuel they need to survive under pressure.
The mouse data came first. A 2017 study published in Science found that oral supplementation with vitamin B3 significantly protected visual function in mice and reduced optic nerve degeneration, even in aged animals predisposed to glaucoma. The human evidence followed. A 2020 Australian clinical trial, published in Clinical and Experimental Ophthalmology, involving 57 glaucoma patients taking 3 grams per day of nicotinamide found improved inner retinal function, a promising signal that the approach might translate from mice to people.
More recently, a 2025 review published in the International Journal of Molecular Sciences synthesized the growing body of evidence, noting that five large-scale observational studies from the United States and South Korea consistently found that people consuming greater amounts of dietary niacin tended to have a lower likelihood of developing glaucoma.
An ongoing phase III randomized controlled trial at Columbia University and Stanford is currently testing a combination of nicotinamide at 3 grams per day alongside calcium pyruvate at 1 gram per day in POAG patients, with outcomes tracking both visual field changes and structural measurements of the optic nerve. Results are projected to help clarify whether the supplement effect is real in a gold-standard trial setting.
This combination approach is notable. Calcium pyruvate is a compound that also supports mitochondrial energy metabolism, potentially complementing nicotinamide’s mechanism. While the 2026 real-world study looked at nicotinamide alone, the title of this article refers to a “vitamin combo” precisely because multiple trials are now investigating whether pairing nicotinamide with pyruvate or other metabolic support compounds could be even more protective.
Read More: Can What You Eat Really Affect Your Eye Health?
The Safety Conversation You Need to Have First
Nicotinamide is sold over the counter and is relatively affordable, which makes it tempting to self-prescribe. That would be a mistake without medical oversight, particularly at higher doses.
Nicotinamide is not approved for glaucoma and its safety at doses used in trials is not fully established. The daily nicotinamide dose used in glaucoma trials, 3 grams per day, is significantly higher than the recommended daily intake of 20 milligrams.
At that dosage level, hepatotoxicity is a genuine concern. Niacin, another form of B3, is directly linked to liver toxicity, so it should never be substituted. According to a 2024 case report in the Journal of Glaucoma, two cases of drug-induced liver injury were reported in glaucoma neuroprotection trials, both involving elevated liver enzymes and other symptoms. In each case, liver function normalized after the supplement was discontinued.
According to the American Academy of Ophthalmology’s safety guidance on nicotinamide, at doses of 3,000 milligrams or more daily, some people have experienced serious side effects including liver toxicity. Importantly, niacin and nicotinamide are not interchangeable. Patients with current or prior liver disease should not take nicotinamide supplementation, and niacin should not be substituted because it is hepatotoxic at high doses.
One advantage nicotinamide does have over niacin at lower therapeutic doses is tolerability. Unlike niacin, nicotinamide doesn’t typically cause the uncomfortable skin flushing that leads many people to abandon niacin supplementation. But that relative comfort should not give a false sense of safety at the multi-gram doses being studied for glaucoma.
Based on laboratory and human studies, nicotinamide holds promise as a potential neuroprotective agent for glaucoma. However, its efficacy and safety continue to be investigated, and its optimal long-term dose is currently unknown.
What About People With Ocular Hypertension Specifically?
While intraocular pressure reduction remains the cornerstone of glaucoma treatment, neuroprotective strategies targeting retinal ganglion cell metabolism are actively being investigated. The 2026 study focused specifically on people with ocular hypertension who had not yet developed glaucoma, a group that gets standard monitoring but few proactive treatment options beyond eye drops.
A 2002 study in JAMA Ophthalmology estimated that three to six million people in the United States alone have elevated intraocular pressure that puts them at increased risk of developing POAG. That’s a large population currently caught in a monitoring holding pattern, watching and waiting for the disease to arrive.
The 2026 findings suggest nicotinamide may extend that window significantly, or, in many cases, keep the disease from arriving at all. That’s a meaningful clinical shift if confirmed by randomized trials. The 66% relative risk reduction observed in this real-world cohort is not a small effect, though observational data has inherent limitations. People who take supplements tend to have other health-conscious behaviors, and nicotinamide use was often not formally recorded by clinicians since it’s sold over the counter.
What to Do Now
Glaucoma doesn’t announce itself. Most people who lose vision to it describe the same thing in hindsight: they didn’t notice anything was wrong until it was already serious. Annual eye exams with intraocular pressure measurement remain the most reliable way to catch elevated eye pressure before the disease takes hold.
If you’ve been told your eye pressure is elevated, that’s the time to have a direct conversation with your ophthalmologist about what the current evidence on nicotinamide actually shows, what dose is being studied, and whether periodic liver function testing would be appropriate if you pursue supplementation. The 2026 JAMA Ophthalmology data is real-world evidence from nearly 3,000 patients across 20 years, and it warrants a serious clinical discussion, not a trip to the supplement aisle without guidance.
The joint position statement from the American Glaucoma Society and American Academy of Ophthalmology recommends that if doses below 3 grams per day are being considered, collaboration with a primary care physician is necessary and periodic liver function testing should be performed. Doses at or above 3 grams per day should be reserved for monitored clinical trial settings.
The research is moving fast. Multiple large randomized trials are currently underway. What’s already clear is that a vitamin once associated mainly with flushing and skin creams has earned a serious place in the conversation about how to protect the cells that make vision possible.
Disclaimer: The author is not a licensed medical professional. The information provided is for general informational and educational purposes only and is based on research from publicly available, reputable sources. It is not intended to constitute, and should not be relied upon as, medical advice, diagnosis, or treatment. Always consult a licensed physician or other qualified healthcare provider regarding any medical condition, symptoms, or medications. Do not disregard, avoid, or delay seeking professional medical advice or treatment because of information contained herein.
AI Disclaimer: This article was created with the assistance of AI tools and reviewed by a human editor.
Read More: This Common Vitamin Could Be Dangerous If You Take Blood Thinners